1. Are you sure AZD0780 is specified as a "Small Molecule" in the referenced material?
2. Are you sure MK-0616 has reached Phase 2b in its current pipeline status, according to the reference?
3. Are you sure the "Natural Phytochemicals Study" qualifies as a small molecule program rather than a different drug modality?
4. Are you sure Alirocumab and Evolocumab have both completed all trial phases and are accurately listed as "approved" with ongoing trials in various phases in the referenced material?
5. Are you sure the reference provided for the Natural Phytochemicals Study validates its pre-clinical status targeting PCSK9 specifically?
6. Are you sure Inclisiran is currently in an ongoing Phase 3 trial, according to the provided references?
7. Are you sure RN0191 has presented positive Phase 1 results in an accurate and recent setting as per the reference?
8. Are you sure all included endpoints in the trial results tables (e.g., LDL-C reduction, cardiovascular outcomes) are aligned and correctly referenced for the respective drug programs?
9. Are you sure the stated endpoints for each trial are accurately reflected in the cited references?
10. Are you sure the rationale provided (preventing the degradation of LDL receptors) is the primary mechanism of action for all the drugs listed in the competitive_edge report?